Detalles de la búsqueda
1.
Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions.
Am J Hum Genet
; 111(6): 1061-1083, 2024 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38723632
2.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med
; 390(12): 1080-1091, 2024 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38507751
3.
The impact of coding germline variants on contralateral breast cancer risk and survival.
Am J Hum Genet
; 110(3): 475-486, 2023 03 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36827971
4.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med
; 386(6): 556-567, 2022 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35139274
5.
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
Int J Cancer
; 155(1): 128-138, 2024 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38447007
6.
Genome-wide association study and functional follow-up identify 14q12 as a candidate risk locus for cervical cancer.
Hum Mol Genet
; 31(15): 2483-2497, 2022 08 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35157032
7.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Breast Cancer Res Treat
; 204(2): 237-248, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38112922
8.
Disentangling the relationships of body mass index and circulating sex hormone concentrations in mammographic density using Mendelian randomization.
Breast Cancer Res Treat
; 206(2): 295-305, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38653906
9.
Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.
Clin Chem
; 70(1): 307-318, 2024 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38175595
10.
Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective.
Strahlenther Onkol
; 200(6): 461-467, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38393398
11.
Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
Gynecol Oncol
; 183: 25-32, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38490057
12.
Association between event-free survival and overall survival in early-stage triple-negative breast cancer.
Future Oncol
; 20(6): 335-348, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37602372
13.
Effects of prenatal alcohol exposition on cognitive outcomes in childhood and youth: a longitudinal analysis based on meconium ethyl glucuronide.
Eur Arch Psychiatry Clin Neurosci
; 274(2): 343-352, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37532863
14.
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Int J Gynecol Cancer
; 34(4): 550-558, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38129136
15.
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel.
J Med Genet
; 60(12): 1186-1197, 2023 Nov 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37451831
16.
Status quo and future directions of digitalization in gynecology and obstetrics in Germany: a survey of the commission Digital Medicine of the German Society for Gynecology and Obstetrics.
Arch Gynecol Obstet
; 309(1): 195-204, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37755531
17.
Correlation of RANK and RANKL with mammographic density in primary breast cancer patients.
Arch Gynecol Obstet
; 2024 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38836929
18.
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Lancet Oncol
; 24(9): 1029-1041, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37657462
19.
A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: application to BRCA1 and BRCA2.
Hum Mutat
; 20232023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38725546
20.
A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry.
Breast Cancer Res
; 25(1): 93, 2023 08 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37559094